Transforming treatments for adult Acute Lymphoblastic Leukemia

About Obe-cel

Clinical-stage programs for hematological and solid tumor indications

Our pipeline

Developing life-changing treatments for cancer patients

Corporate presentations
1/3

Who we are

Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients and is building a fully integrated, next-generation CAR T company

About us

Our Technology

Chimeric Antigen Receptors

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Advanced Cell Programming

Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.

T Cell Manufacturing

We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.

Explore our technology

Obe-cel

The company’s lead therapeutic candidate, obe-cel, is a potentially transformational treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile results in increased T cell persistence leading to high levels of durable remissions and remarkably low levels of cytokine release syndrome and other immunotoxicities. Obe-cel is currently being evaluated in the potentially pivotal FELIX study in adult ALL and in phase 1 studies for other B-NHL indications. Obe-cel phase 2 pivotal FELIX clinical trial met its primary endpoint at an interim analysis in 2022 with additional data expected in mid-2023.

Find out more

Our Obe-cel Abstracts and Publications

See all
AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
December 11 2022

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (B-ALL) and Other B-Cell Malignancies

American Society of Hematology Annual Meeting
December 13 2021

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Latest news

Get the latest updates from Autolus on new research, company news and events

View all news

Information for patients

Clinical trials are required to gain regulatory approval for new medicines to advance patient care.

Learn more about our CAR T cell therapy clinical trials

Life at Autolus

Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.

Careers at Autolus

Investors

Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

View investor information